Absolute/Relative Bioavailability and Metabolism of Dodeca-2E,4E,8Z,10E/Z-Tetraenoic Acid Isobutylamides (Tetraenes) after Intravenous and Oral Single Doses to Rats

Abstract

The present study assessed the absolute and relative bioavailabilities of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (tetraenes), the main bioactive constituents in Echinacea, administered as pure compounds or in the form of an Echinacea purpurea root extract preparation. Tetraenes were administered orally by gavage or intravenously in a dose of 0.75 mg/kg. The extract was administered orally in a dose of 158.6 mg/kg which corresponds to the same amount of tetraenes. Pharmacokinetic parameters of tetraenes were calculated by non-compartmental analysis using WinNonlin® 5.2 software. Mean dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide dose-normalized plasma area under the concentration-time curve (AUC_0–∞/dose) was 3.24 ± 0.32 min · ng/mL/µg and 0.95 ± 0.16 min · ng/mL/µg after iv and oral administrations, respectively, and 1.53 ± 0.18 min · ng/mL/µg after oral administration of the Echinacea root extract. The absolute oral bioavailability of dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides was 29.2 ± 2.3 %, which was increased to 47.1 ± 7.2 % (1.6-fold) by administration of the Echinacea extract. Administration of an Echinacea extract increased blood exposure with no impact on C_max, but prolonged the elimination half-life to 123.3 ± 15.7 min in comparison to 35.8 ± 6.5 min after administration of the pure dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides.

Key words

Echinacea - Asteraceae - dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides - absolute bioavailability - relative bioavailability - LC-MS

References

• 1 Bauer R. Chemistry, analysis and immunological investigations of Echinacea phytopharmaceuticals. In: Wagner H, editor Immunomodulatory agents from plants. Basel, Boston, Berlin: Birkhäuser Verlag; 1999: 41-88
• 2 Woelkart K, Xu W, Pei Y, Makriyannis A, Picone R P, Bauer R. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.  Planta Med. 2005;  71 701-705
• 3 Woelkart K, Bauer R. The role of alkamides as an active principle of Echinacea.  Planta Med. 2007;  73 615-623
• 4 Woelkart K, Salo-Ahen O H M, Bauer R. CB receptor ligands from plants.  Curr Top Med Chem. 2008;  8 173-186
• 5 Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-α gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways.  FEBS Lett. 2004;  577 563-569
• 6 Burger R A, Torres A R, Warren R P, Caldwell V D, Hughes B D. Echinacea-induced cytokine production by human macrophages.  Int J Immunopharmacol. 1997;  19 371-379
• 7 Goel V, Chang C, Slama J V, Barton R, Bauer R, Gahler R. Echinacea stimulates macrophage function in the lung and spleen of normal rats.  J Nutr Biochem. 2002;  13 487-492
• 8 Rininger J A, Kickner S, Chigurupati P, McLean A, Franck Z. Immunopharmacological activity of Echinacea preparations following simulated digestion on murine macrophages and human peripheral blood cells.  J Leukoc Biol. 2000;  68 503-510
• 9 Matthias A, Banbury L, Stevenson L M, Bone K M, Leach D N, Lehmann R P. Alkylamides from Echinacea modulate induced immune responses in macrophages.  Immunol Invest. 2007;  36 117-130
• 10 Matthias A, Blanchfield J T, Penman K G, Toth I, Lang C S, De Voss J J, Lehmann R P. Permeability studies of alkylamides and caffeic acid conjugates from Echinacea using a Caco-2 cell monolayer model.  J Clin Pharm Ther. 2004;  29 7-13
• 11 Woelkart K, Koidl C, Grisold A, Gangemi J D, Turner R B, Marth E, Bauer R. Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans.  J Clin Pharmacol. 2005;  45 683-689
• 12 Woelkart K, Marth E, Raggam R, Suter A, Schoop R, Koidl C, Kleinhappl B, Bauer R. Bioavailability and pharmacokinetic studies on Echinacea purpurea preparations and their interaction with the immune system.  Int J Clin Pharmacol Ther. 2006;  44 401-408
• 13 Woelkart K, Dittrich P, Beubler E, Pinl F, Schoop R, Suter A, Bauer R. Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans.  Planta Med. 2008;  74 651-656
• 14 Matthias A, Addison R S, Agnew L L, Bone K M, Watson K, Lehmann R P. Comparison of Echinacea alkylamide pharmacokinetics between liquid and tablet preparations.  Phytomedicine. 2007;  14 587-590
• 15 Matthias A, Gillam E M J, Penman K G, Matovic N J, Bone K M, De Voss J J, Lehmann R P. Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes.  Chem Biol Interact. 2005;  155 62-70
• 16 Xing J, Xie C F, Lou H X. Recent applications of liquid chromatography-mass spectrometry in natural products bioanalysis.  J Pharm Biomed. 2007;  44 368-378
• 17 ESCOP Monographs. The Scientific Foundation for Herbal Medicinal Products. Stuttgart, New York: Thieme Verlag; 2003
• 18 Monograph of the German Commission E, B. Anz. No. 162 from 29.08.1992. Köln: Bundesanzeiger Verlagsgesellschaft; 1992
• 19 Rucker R B. Allometric scaling, metabolic body size and interspecies comparisons of basal nutritional requirements.  J Anim Physiol Anim Nutr. 2007;  91 148-156
• 20 Zeller W, Weber H, Panoussis B, Bürge T, Bergmann R. Refinement of blood sampling from the sublingual vein of rats.  Lab Anim UK. 1998;  32 369-376
• 21 Woelkart K, Frye R F, Bauer R, Derendorf H, Butterweck V. Pharmacokinetics and tissue distribution of dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides (“tetraene”) after oral administration in rats.  Planta Med. 2009;  75 1306-1313
• 22 Bu W, Myers N, McCarty J D, O'Neill T, Hollar S, Stetson P L, Sved D W. Simultaneous determination of six urinary porphyrins using liquid chromatograph-tandem mass spectrometry.  J Chromatogr B Anal Technol Biomed Life Sci. 2003;  783 411-423
• 23 Schilcher H. Standardisierung, Kontrolle und Qualitätsprüfung von nichttoxischen flüssigen Arzneipflanzenzubereitungen.  Arzneimittelstandardisierung. 1965;  6 649-655
• 24 Menßen H G. Standardisierte Arzneien aus Heilpflanzen und ihre Bedeutung für die moderne Phytotherapie.  Therapiewoche. 1968;  18 1432-1433
• 25 Eder M, Mehnert W. Pflanzliche Begleitstoffe – wertvolle Hilfsstoffe oder überflüssiger Ballast?.  Pharm unserer Zeit. 2000;  29 377-384
• 26 Yata N N, Sugihara R, Yamajo T, Murakami Y, Higashi H, Kimata K, Nakayama T, Kuzuki T, Tanaka O. Enhanced small intestinal absorption of beta-lactam antibiotics in rats in the presence of monodesmosides from pericarps of Sapindus mukurossi (Ennmei-hi).  J Pharmacobiodyn. 1986;  9 211-217
• 27 Hänsel R, Sticher O, Steinegger E. Pharmakognosie – Phytopharmazie. Berlin, Heidelberg: Springer-Verlag; 1999
• 28 Keledjian J, Duffield P H, Janieson D D, Lidgard R O, Duffield A M. Uptake into mouse brain of four compounds present in the psychoactive beverage Kava.  J Pharm Sci. 1988;  77 1003-1006
• 29 Biber A, Nöldner M, Schlegelmilch R. Development of a formulation of Kava-Kava extract through pharmacokinetic experiments in animals.  Naunyn Schmiedebergs Arch Pharmacol. 1992;  345 R24
• 30 Vinson J A, Bose P. Comparative bioavailability to humans of ascorbic acid alone or in a citrus extract.  Am J Clin Nutr. 1988;  48 601-604
• 31 List P H, Schmid W, Weil E. Reinsubstanz oder galenische Zubereitung.  Drug Res. 1969;  19 181-185
• 32 Butterweck V. Mechanism of action of St. John's wort in depression: what is known?.  CNS Drugs. 2003;  17 539-562
• 33 Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. Step by step removal of hyperforin and hypericin: activity profile of different Hypericum preparations in behavioral models.  Life Sci. 2003;  73 627-639
• 34 Butterweck V, Petereit F, Winterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test.  Planta Med. 1998;  64 291-294